Yahoo Finance

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

Data shows that INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with clinical benefit as measured by reduced need for surgeries PLYMOUTH ...
Finanznachrichten

INOVIO Pharmaceuticals, Inc.: Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature ...

Highlights from the Nature Communications Paper 81.3% (26/32) of patients had a decrease of at least one surgical intervention from the prior year (defined as the Overall Clinical Response Rate) after ...